To appraise the clinical and cost-effectiveness of daratumumab in combination with Bortezomib, thalidomide and dexamethasone within its marketing authorisation for multiple myeloma
Status In progress
Process STA 2018
ID number 1510

Project Team

Project lead Michelle Adhemar

Email enquiries


Key events during the development of the guidance:

Date Update
08 May 2019 In progress, Referred 21 March 2017
09 January 2019 - 06 February 2019 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance